Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2023;47:668-81)
Diabetes Metab J. 2023 Nov;47(6):879-881. doi: 10.4093/dmj.2023.0328. Epub 2023 Nov 24.NO ABSTRACTPMID:38043783 | PMC:PMC10695716 | DOI:10.4093/dmj.2023.0328 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - December 3, 2023 Category: Endocrinology Authors: Da Young Lee Source Type: research
Effects of the treatment with liraglutide early after surgical in-tervention on clinical outcomes in patients with short bowel syndrome. A pilot observational “real-life” study
Rationale: Liraglutide, a glucagon-like peptide-1 agonist, has shown beneficial effects on fecal output in short bowel syndrome (SBS) by small human studies. The potential effects early after gut resection are not known. In this pilot observational study, we described the effects of administration of liraglutide in a cohort of 19 adult patients with a new SBS diagnosis, within 1-month after surgical resection. (Source: Clinical Nutrition ESPEN)
Source: Clinical Nutrition ESPEN - December 1, 2023 Category: Nutrition Authors: F.D. Merlo, U. Aimasso, M. Ossola, M. Ippolito, L. Cravero, V. Ponzo, S. Bo Source Type: research
HPR2 Baseline Characteristics of Patients Applying for Reimbursment of Liraglutide (Saxenda ®) for Weight Management Under a Managed Access Protocol in Ireland
To review baseline characteristics of applicants seeking reimbursement for liraglutide (Saxenda ®) for weight management, under a managed access protocol (MAP) operated by the Health Service Executive-Medicines Management Programme (HSE-MMP) in Ireland. In Phase I, Saxenda® is reimbursed for patients with a body mass index (BMI)>35kg/m2, with prediabetes and high-risk for cardiovascular disease. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: C. Gorry, M. Daly, S. Doran, K. Finnigan, S. Clarke, M. Barry Source Type: research
Liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit
CONCLUSION: We observed a high discontinuation rate in real-life clinical setting, where Liraglutide 3.0 therapy is paid out-of-pocket. While psychiatric symptoms might play a role in diminishing adherence to therapy, they do not prevent drug's effectiveness to promote weight loss. This finding underscores the potential advantages of liraglutide 3.0 mg therapy for individuals contending with obesity while simultaneously managing mental health challenges.LEVEL OF EVIDENCE: Level V, descriptive studies.PMID:38015342 | DOI:10.1007/s40519-023-01625-5 (Source: Eating and weight disorders : EWD)
Source: Eating and weight disorders : EWD - November 28, 2023 Category: Eating Disorders & Weight Management Authors: Silvia Tempia Valenta Michele Stecchi Federica Perazza Chiara Nuccitelli Nicola Villanova Loris Pironi Anna Rita Atti Maria Letizia Petroni Source Type: research
Seladelpar combined with complementary therapies improves fibrosis, inflammation and liver injury in a mouse model of nonalcoholic steatohepatitis
Am J Physiol Gastrointest Liver Physiol. 2023 Nov 28. doi: 10.1152/ajpgi.00158.2023. Online ahead of print.ABSTRACTSeladelpar, a selective PPARδ agonist, improves markers of hepatic injury in human liver diseases, but histological improvement of nonalcoholic steatohepatitis (NASH) and liver fibrosis has been challenging with any single agent. To discover how complimentary agents could work with seladelpar to achieve optimal outcomes, this study evaluated a variety of therapeutics (alone and in combination) in a mouse model of NASH. Mice on a high fat Amylin Liver NASH (AMLN) diet were treated for 12 weeks with seladelpar,...
Source: American Journal of Physiology. Gastrointestinal and Liver Physiology - November 28, 2023 Category: Physiology Authors: Yun-Jung Choi Jeffrey D Johnson Jin-Ju Lee Jiangao Song Marcy Matthews Marc K Hellerstein Charles A McWherter Source Type: research
Seladelpar combined with complementary therapies improves fibrosis, inflammation and liver injury in a mouse model of nonalcoholic steatohepatitis
Am J Physiol Gastrointest Liver Physiol. 2023 Nov 28. doi: 10.1152/ajpgi.00158.2023. Online ahead of print.ABSTRACTSeladelpar, a selective PPARδ agonist, improves markers of hepatic injury in human liver diseases, but histological improvement of nonalcoholic steatohepatitis (NASH) and liver fibrosis has been challenging with any single agent. To discover how complimentary agents could work with seladelpar to achieve optimal outcomes, this study evaluated a variety of therapeutics (alone and in combination) in a mouse model of NASH. Mice on a high fat Amylin Liver NASH (AMLN) diet were treated for 12 weeks with seladelpar,...
Source: Am J Physiol Gastroi... - November 28, 2023 Category: Gastroenterology Authors: Yun-Jung Choi Jeffrey D Johnson Jin-Ju Lee Jiangao Song Marcy Matthews Marc K Hellerstein Charles A McWherter Source Type: research
Seladelpar combined with complementary therapies improves fibrosis, inflammation and liver injury in a mouse model of nonalcoholic steatohepatitis
Am J Physiol Gastrointest Liver Physiol. 2023 Nov 28. doi: 10.1152/ajpgi.00158.2023. Online ahead of print.ABSTRACTSeladelpar, a selective PPARδ agonist, improves markers of hepatic injury in human liver diseases, but histological improvement of nonalcoholic steatohepatitis (NASH) and liver fibrosis has been challenging with any single agent. To discover how complimentary agents could work with seladelpar to achieve optimal outcomes, this study evaluated a variety of therapeutics (alone and in combination) in a mouse model of NASH. Mice on a high fat Amylin Liver NASH (AMLN) diet were treated for 12 weeks with seladelpar,...
Source: American Journal of Physiology. Gastrointestinal and Liver Physiology - November 28, 2023 Category: Physiology Authors: Yun-Jung Choi Jeffrey D Johnson Jin-Ju Lee Jiangao Song Marcy Matthews Marc K Hellerstein Charles A McWherter Source Type: research
Liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit
CONCLUSION: We observed a high discontinuation rate in real-life clinical setting, where Liraglutide 3.0 therapy is paid out-of-pocket. While psychiatric symptoms might play a role in diminishing adherence to therapy, they do not prevent drug's effectiveness to promote weight loss. This finding underscores the potential advantages of liraglutide 3.0 mg therapy for individuals contending with obesity while simultaneously managing mental health challenges.LEVEL OF EVIDENCE: Level V, descriptive studies.PMID:38015342 | DOI:10.1007/s40519-023-01625-5 (Source: Eating and weight disorders : EWD)
Source: Eating and weight disorders : EWD - November 28, 2023 Category: Eating Disorders & Weight Management Authors: Silvia Tempia Valenta Michele Stecchi Federica Perazza Chiara Nuccitelli Nicola Villanova Loris Pironi Anna Rita Atti Maria Letizia Petroni Source Type: research
Seladelpar combined with complementary therapies improves fibrosis, inflammation and liver injury in a mouse model of nonalcoholic steatohepatitis
Am J Physiol Gastrointest Liver Physiol. 2023 Nov 28. doi: 10.1152/ajpgi.00158.2023. Online ahead of print.ABSTRACTSeladelpar, a selective PPARδ agonist, improves markers of hepatic injury in human liver diseases, but histological improvement of nonalcoholic steatohepatitis (NASH) and liver fibrosis has been challenging with any single agent. To discover how complimentary agents could work with seladelpar to achieve optimal outcomes, this study evaluated a variety of therapeutics (alone and in combination) in a mouse model of NASH. Mice on a high fat Amylin Liver NASH (AMLN) diet were treated for 12 weeks with seladelpar,...
Source: Am J Physiol Gastroi... - November 28, 2023 Category: Gastroenterology Authors: Yun-Jung Choi Jeffrey D Johnson Jin-Ju Lee Jiangao Song Marcy Matthews Marc K Hellerstein Charles A McWherter Source Type: research
Seladelpar combined with complementary therapies improves fibrosis, inflammation and liver injury in a mouse model of nonalcoholic steatohepatitis
Am J Physiol Gastrointest Liver Physiol. 2023 Nov 28. doi: 10.1152/ajpgi.00158.2023. Online ahead of print.ABSTRACTSeladelpar, a selective PPARδ agonist, improves markers of hepatic injury in human liver diseases, but histological improvement of nonalcoholic steatohepatitis (NASH) and liver fibrosis has been challenging with any single agent. To discover how complimentary agents could work with seladelpar to achieve optimal outcomes, this study evaluated a variety of therapeutics (alone and in combination) in a mouse model of NASH. Mice on a high fat Amylin Liver NASH (AMLN) diet were treated for 12 weeks with seladelpar,...
Source: American Journal of Physiology. Gastrointestinal and Liver Physiology - November 28, 2023 Category: Physiology Authors: Yun-Jung Choi Jeffrey D Johnson Jin-Ju Lee Jiangao Song Marcy Matthews Marc K Hellerstein Charles A McWherter Source Type: research
Liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit
CONCLUSION: We observed a high discontinuation rate in real-life clinical setting, where Liraglutide 3.0 therapy is paid out-of-pocket. While psychiatric symptoms might play a role in diminishing adherence to therapy, they do not prevent drug's effectiveness to promote weight loss. This finding underscores the potential advantages of liraglutide 3.0 mg therapy for individuals contending with obesity while simultaneously managing mental health challenges.LEVEL OF EVIDENCE: Level V, descriptive studies.PMID:38015342 | PMC:PMC10684642 | DOI:10.1007/s40519-023-01625-5 (Source: Eating and weight disorders : EWD)
Source: Eating and weight disorders : EWD - November 28, 2023 Category: Eating Disorders & Weight Management Authors: Silvia Tempia Valenta Michele Stecchi Federica Perazza Chiara Nuccitelli Nicola Villanova Loris Pironi Anna Rita Atti Maria Letizia Petroni Source Type: research
Seladelpar combined with complementary therapies improves fibrosis, inflammation and liver injury in a mouse model of nonalcoholic steatohepatitis
Am J Physiol Gastrointest Liver Physiol. 2023 Nov 28. doi: 10.1152/ajpgi.00158.2023. Online ahead of print.ABSTRACTSeladelpar, a selective PPARδ agonist, improves markers of hepatic injury in human liver diseases, but histological improvement of nonalcoholic steatohepatitis (NASH) and liver fibrosis has been challenging with any single agent. To discover how complimentary agents could work with seladelpar to achieve optimal outcomes, this study evaluated a variety of therapeutics (alone and in combination) in a mouse model of NASH. Mice on a high fat Amylin Liver NASH (AMLN) diet were treated for 12 weeks with seladelpar,...
Source: Am J Physiol Gastroi... - November 28, 2023 Category: Gastroenterology Authors: Yun-Jung Choi Jeffrey D Johnson Jin-Ju Lee Jiangao Song Marcy Matthews Marc K Hellerstein Charles A McWherter Source Type: research
Seladelpar combined with complementary therapies improves fibrosis, inflammation and liver injury in a mouse model of nonalcoholic steatohepatitis
Am J Physiol Gastrointest Liver Physiol. 2023 Nov 28. doi: 10.1152/ajpgi.00158.2023. Online ahead of print.ABSTRACTSeladelpar, a selective PPARδ agonist, improves markers of hepatic injury in human liver diseases, but histological improvement of nonalcoholic steatohepatitis (NASH) and liver fibrosis has been challenging with any single agent. To discover how complimentary agents could work with seladelpar to achieve optimal outcomes, this study evaluated a variety of therapeutics (alone and in combination) in a mouse model of NASH. Mice on a high fat Amylin Liver NASH (AMLN) diet were treated for 12 weeks with seladelpar,...
Source: American Journal of Physiology. Gastrointestinal and Liver Physiology - November 28, 2023 Category: Physiology Authors: Yun-Jung Choi Jeffrey D Johnson Jin-Ju Lee Jiangao Song Marcy Matthews Marc K Hellerstein Charles A McWherter Source Type: research
Liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit
CONCLUSION: We observed a high discontinuation rate in real-life clinical setting, where Liraglutide 3.0 therapy is paid out-of-pocket. While psychiatric symptoms might play a role in diminishing adherence to therapy, they do not prevent drug's effectiveness to promote weight loss. This finding underscores the potential advantages of liraglutide 3.0 mg therapy for individuals contending with obesity while simultaneously managing mental health challenges.LEVEL OF EVIDENCE: Level V, descriptive studies.PMID:38015342 | PMC:PMC10684642 | DOI:10.1007/s40519-023-01625-5 (Source: Eating and weight disorders : EWD)
Source: Eating and weight disorders : EWD - November 28, 2023 Category: Eating Disorders & Weight Management Authors: Silvia Tempia Valenta Michele Stecchi Federica Perazza Chiara Nuccitelli Nicola Villanova Loris Pironi Anna Rita Atti Maria Letizia Petroni Source Type: research
Seladelpar combined with complementary therapies improves fibrosis, inflammation and liver injury in a mouse model of nonalcoholic steatohepatitis
Am J Physiol Gastrointest Liver Physiol. 2023 Nov 28. doi: 10.1152/ajpgi.00158.2023. Online ahead of print.ABSTRACTSeladelpar, a selective PPARδ agonist, improves markers of hepatic injury in human liver diseases, but histological improvement of nonalcoholic steatohepatitis (NASH) and liver fibrosis has been challenging with any single agent. To discover how complimentary agents could work with seladelpar to achieve optimal outcomes, this study evaluated a variety of therapeutics (alone and in combination) in a mouse model of NASH. Mice on a high fat Amylin Liver NASH (AMLN) diet were treated for 12 weeks with seladelpar,...
Source: Am J Physiol Gastroi... - November 28, 2023 Category: Gastroenterology Authors: Yun-Jung Choi Jeffrey D Johnson Jin-Ju Lee Jiangao Song Marcy Matthews Marc K Hellerstein Charles A McWherter Source Type: research
